巨大戟醇甲基丁烯酸酯治疗光化性角化病的机制  

Mechanism of ingenol methacrylate in the treatment of actinic keratosis

作　　者：陈惠雅 胡力丹 何黎[1] 徐丹[1] CHEN Huiya;HU Lidan;HE Li;XU Dan(The First Affiliated Hospital of Kunming Medical University,Kunming,Yunnan 650032,China)

机构地区：[1]昆明医科大学第一附属医院皮肤科,云南昆明650032

出　　处：《皮肤病与性病》2022年第6期447-450,共4页Dermatology and Venereology

基　　金：国家自然科学基金(82160598,81660518);云南省皮肤与免疫性疾病临床医学中心(ZX2019-03-02)。

摘　　要：光化性角化病(AK)是一种慢性皮肤病,是侵袭性鳞状细胞癌(SCC)最常见的癌前病变,其发病与长期暴露于紫外线(UV)辐射及其累积效应,导致角质形成细胞增殖和凋亡失控有关。AK的治疗主要是针对病变区域的局部治疗。2012年,美国食品药品监督管理局和欧洲药品管理局批准Picato凝胶制剂用于治疗光化性角化病,其主要成分是巨大戟醇甲基丁烯酸酯(IngMeb)。此篇综述主要总结了IngMeb在治疗AK中可能的作用机制。Actinic keratosis(AK)is a kind of chronic skin disease that results in uncontrolled proliferation and apoptosis of keratinocytes due to prolonged exposure or cumulative effects of ultraviolet(UV)radiation.AK is the most common precancerous lesion in invasive squamous cell carcinoma(SCC). The treatment of AK is mainly aimed at the local treatment of the lesion area.In 2012,the US Food and Drug Administration(FDA)and the European Drug Administration(EDA)approved the treatment of actinic keratosis with Picato gel,the main ingredient of which is megaphorol methyl butenoate(IngMeb).This review mainly summarizes the possible mechanisms of IngMeb in the treatment of AK.

关 键 词：光化性角化病 巨大戟醇甲基丁烯酸酯 机制 

分 类 号：R758.6[医药卫生—皮肤病学与性病学]